adagrasib
mirati
['lcsm,(-blcsm)', 'sclc', 'krystal1', 'nsclc', 'adagrasib']
krystal1: adagrasib in patients with kras g12c mutant nsclc previously treatment with io+/-io (n=112, evaluable)--&gt; orr=43% dcr 80% md dor 8.5 months; intracranial (n=33) orr 33% &amp; dor 11.2 months #asco22 #lcsm 
Assistant Prof | Thoracic Oncology & Phase-I  @karmanoscancer | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb @bpkihsofficial | Views/Tweets my own